Press Ganey Launches Segmentation White Paper
Onxeo Announces First Outcomes of Livatag® Preclinical Plan
Ceridian CEN is set be acquired after shareholders finally approved the $36 per share offer from Thomas H . Lee Partners and Fidelity National Financial FNF. We expect the deal to be completed before the end of the year.
Onxeo S.A.: Combination of AsiDNA and PARP Inhibitors Demonstrates Synergistic Effect, Bypasses Genetic Restriction
UPDATE: A 3-year low for this contrarian indicator may be a screaming buy signal